Article Text

Download PDFPDF

Subject index

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

γδ-T cells, A19,  P06.01

3p-RNA, A27,  P08.06

a-CTLA-4, A22,  P06.07

ACT, A4,  P01.03

Acute Myeloid Leukemia, A4,  P01.04

adenosine, A26,  P08.05

Adoptive T cell therapy, A20, A22,  P06.03, P07.01

AML, A22,  P07.01

anti-IL8, anti-PD1, Myeloid cells, A24,  P08.01

artificial intelligence, A8, A9,  P02.03, P02.06

Automated PD-L1 quantification, A8,  P02.03

B7-H3, A5,  P01.05

biomarker, A30,  P09.05

Bispecific antibodies, A20, A22,  P06.03, P07.01

BiTEs, A24,  P07.03

breast cancer, A11, A20,  P02.09, P06.04

Cancer immunotherapy, A1, A26,  10.01, P08.04

Cancer Testis Antigens, A2, A19,  10.04, P06.02

cancer vaccine, A28,  P09.03

CAR T cell therapy, A21,  P06.06

CAR T cells, A16, A24, A26, A27,  P04.01, P07.03, P08.05, P08.06

carcinoma, A2,  10.03

CCL22, A3,  P01.02

CCR2/CCR5, A25,  P08.02

CD155, A2,  10.03

CD19 CAR-T cells, A23,  P07.02

CD40-activated B cells, A21,  P06.05

CD8 T cells, A15,  P03.07

cellular anti-tumor immune responses, A19,  P06.02

central tolerance, A15,  P03.07

Checkpoint inhibition, A17,  P04.02

Chemokine receptors, A1, A21,  10.01, P06.06

Chemotherapy, A4, A31,  P01.04, P09.07

cold tumours, A14,  P03.04

CpG (ODN1826), CpG (ODN2006), A3,  P01.02

CTLA-4, A25,  P08.03

CTLA-4 immunohistochemistry, A9,  P02.06

Cytokine release syndrome, A27,  P09.01

Diffuse Large B-Cell Lymphoma, A16,  P04.01

endometrial cancer, A9,  P02.04

engineered transcription factor, A23,  P07.02

esophago-gastric adenocarcinoma, A21,  P06.05

hepatocellular carcinoma, A3,  P01.01

HER2/neu, A28,  P09.03

Heterologous prime-boost, A13,  P03.02

high-throughput screening, A18,  P05.01

HLA-homozygosity, A1,  10.02

humanized mice, A22,  P06.07

Hyaluronic acid, A28,  P09.03

IL-22, A2,  10.03

immune checkpoint inhibitors, A5, A7,  P01.06, P01.08

immune checkpoints, A31,  P09.07

Immune regulation, A8,  P02.02

Immuno PET, A17,  P04.04

Immunogenicity, A14, A28,  P03.03, P09.02

immunohistochemistry, A10,  P02.08

Immunomonitoring, A16,  P04.01

immunosuppression, A7, A10, A29,  P02.01, P02.08, P09.04

Immunotherapy, A8, A15, A19, A29, A30, A30,  P02.02, P03.06, P06.01, P09.04, P09.05, P09.06

Immunotoxicities, A24,  P07.03

In vivo tumor models, A26,  P08.04

Killing assay, A18,  P05.01

kinase inhibitors, A27,  P09.01

LDHC, A20,  P06.04

Liver transplant, A3,  P01.01

Lung cancer, A5, A9, A12,  P01.05, P02.05, P02.10

Melanoma, A10, A17, A20, A22,  P02.08, P04.02, P06.03, P06.07

metabolism, A31,  P09.07

metastases, A6,  P01.07

MHC class I, A28,  P09.02

multiplex fluorescence immunohistochemistry, A8,  P02.03

myeloid, A12,  P02.11

Nanostring, A17,  P04.03

Nasopharyngeal carcinoma, A30,  P09.06

Neoadjuvant therapy, A3,  P01.01

Neoantigens, A1, A13, A14, A14, A25,  10.02, P03.01, P03.03, P03.04, P08.03

neoepitope, A15,  P03.06

Neuroblastoma, A19, A28,  P06.01, P09.02

neutrophils, A11,  P02.09

NFAT, A23,  P07.02

non-coding, A14,  P03.04

NSCLC, A17,  P04.03

Oncolytic virus, A13,  P03.02

overweight, A5,  P01.06

pancreatic cancer, A25, A27,  P08.02, P08.06

PD-L1, A17, A20,  P04.04, P06.04

posterior fossa A ependymoma, A10,  P02.07

presentation prediction, A14,  P03.03

Protection, A26,  P08.04

Protein-based vaccine, A13,  P03.02

radiation, A25,  P08.02

Radiotherapy, A17,  P04.04

RCC, A4,  P01.03

reprogramming, A12,  P02.11

sarcopenia, A7,  P01.08

Single cell multi-omics analysis, A12,  P02.10

single cell sequencing, A9,  P02.05

Solid tumors, A1,  10.01

Surgery, A17, A29,  P04.03, P09.04

survival outcome, A5,  P01.06

survival outcomes, A7,  P01.08

synthetic agonistic receptor T cells, A21,  P06.06

T cell engagers, A27,  P09.01

T cell receptor, A2, A17,  10.04, P04.02

TAMs, A6,  P01.07

TCR-gene therapy, A2,  10.04

tertiary lymphocyte structures, A19,  P06.02

Th9 cells, A9,  P02.04

thymus, A15,  P03.07

TNBC, A6,  P01.07

Toll-Like-Receptor 9 (TLR9), A3,  P01.02

transplantation, A7,  P02.01

TREM1, A12,  P02.11

tumor immune microenvironment, A7, A10,  P02.01, P02.07

tumor immunity, A1,  10.02

Tumor microenvironment, A8, A9, A9, A9, A30,  P02.02, P02.04, P02.05, P02.06, P09.05

Tumor variants and microenvironment, A12,  P02.10

Tumor-associated antigens, A21,  P06.05

Ubiquitin, A5,  P01.05

uPA-PAI-1, A11,  P02.09

Vaccination, A15,  P03.06

Vaccine, A13, A25,  P03.01, P08.03

Virus-Like Particle, A13,  P03.01

Vpx, A4,  P01.04